The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland

BACKGROUND: Biological drugs are generally expensive and produce a continuously growing share of drug costs. Yet they are essential in the treatment of many chronic diseases. Biosimilars, clinically equivalent to biological originator products, are expected to restrain drug costs in the biological m...

Descripción completa

Detalles Bibliográficos
Autores principales: Luukkanen, Saana V., Tolonen, Hanna M., Airaksinen, Marja, Saarukka, Laura S. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271098/
https://www.ncbi.nlm.nih.gov/pubmed/35793041
http://dx.doi.org/10.1007/s40259-022-00540-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271098/
https://www.ncbi.nlm.nih.gov/pubmed/35793041
http://dx.doi.org/10.1007/s40259-022-00540-y

Ejemplares similares